Medical technology company Biotronik has announced the first global implant of its BIOMONITOR IV implantable cardiac monitor (ICM) with artificial intelligence (AI).
Montefiore Einstein Medicine Professor Dr Luigi Di Biase carried out the first procedure with the system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Di Biase said: “The data shows that these new features have the potential to reduce false positive alerts for our patients and allow us to focus on actionable events, providing more efficient care.”
The ICM integrates the company’s SmartECG technology with AI to lower all false positive detections by 86% and preserve 98% of true episodes.
It is claimed to be the only ICM that can differentiate between premature atrial contractions and premature ventricular contractions, helping healthcare professionals to use better tools for risk stratification and diagnosis.
The ICM has a long battery life and wireless connectivity, which allows seamless data transmission and remote monitoring, enabling to avoid frequent in-person clinic visits.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFurthermore, the company provides a simple electronic health record data integration capability, which helps enhance the workflow of a clinic significantly.
In April this year, Biotronik announced that its MATRIX study demonstrated the high detection accuracy of DX single-lead implantable cardioverter-defibrillator (ICD) systems for atrial fibrillation in single-chamber ICD patients.
Biotronik offers cardiovascular, endovascular and neuromodulation solutions for patients with heart and blood vessel diseases as well as chronic pain.
Based in Berlin, Germany, the company conducts operations in more than 100 countries.
